Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CDA | P32320 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16310934 | 1.00 | MAPT (0.59) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL19807412 | 1.00 | MAPT (0.59) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL16311178 | 1.00 | MAPT (0.59) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL19954878 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL15276430 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL16310906 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL19807513 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL16138519 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL20172581 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB | |
| SCHEMBL15279705 | 0.88 | MAPT (0.56) | MAPTCDALMNAMTORTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220135611-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2022-05-05 | — | — | US | disclosed |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-06 | — | — | US | disclosed |
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3449925-B1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | UNIV TUFTS (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10544183-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-9789131-B1 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | MAPT 216/4885CDA 572/4885LMNA 1872/4885 |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | MAPT 216/4885CDA 572/4885LMNA 1872/4885 |
| US-10544183-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | MAPT 216/4885CDA 572/4885LMNA 1872/4885 |
| US-20220135611-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | MAPT 216/4885CDA 572/4885LMNA 1872/4885 |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | MAPT 808/4885CDA 2965/4885LMNA 573/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | MAPT 808/4885CDA 2965/4885LMNA 573/4885 |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | MAPT 808/4885CDA 2965/4885LMNA 573/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | MAPT 808/4885CDA 2965/4885LMNA 573/4885 |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | MAPT 808/4885CDA 2965/4885LMNA 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.